Active Biotech AB's Partner Ipsen Initiates a Proof-of-Concept Study With Tasquinimod in Additional Cancer Indications

Lund, Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release here) will initiate a new phase II, proof-of-concept clinical trial with tasquinimod in a so-called umbrella study evaluating the compound in four different tumor types.

Back to news